Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Gastroesophageal adenocarcinoma
Randomized controlled trials
Systemic therapy
Treatment sequencing
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
26
03
2021
accepted:
02
07
2021
pubmed:
22
7
2021
medline:
26
10
2021
entrez:
21
7
2021
Statut:
ppublish
Résumé
Platinum and fluoropyrimidine combinations typically comprise first-line (1L) therapy in advanced gastric cancer or gastroesophageal junction adenocarcinoma (G/GEA), although controversy exists regarding the use of 5doublet versus triplet cytotoxic regimens. Historically, second-line (2L) and third-line or later (3L+) therapy has been fragmented. Recent trials have increased the need for optimal treatment sequencing in advanced G/GEA. We conducted a systematic search of peer-reviewed manuscripts of randomized clinical trials examining 1L, 2L, and 3L+ therapy for advanced G/GEA published from 2009 through November 19, 2019. When available, overall survival, progression-free survival, time to progression, overall response rate, and toxicity were extracted from each and compared descriptively. In 1L therapy, chemotherapy triplets demonstrated variable efficacy improvements with invariable increased toxicity compared with platinum/fluoropyrimidine doublets. Currently, the only published report of positive outcomes using biologics in 1L describes adding trastuzumab in HER2-overexpressing advanced G/GEA. In 2L, doublet chemotherapy regimens are not uniformly more efficacious than single-agent taxanes or irinotecan, and ramucirumab has demonstrated improved outcomes both as monotherapy and in combination. For advanced G/GEA, review of trial results from 2009-2019 support 1L therapy with platinum and fluoropyrimidine and sequencing with taxanes or irinotecan in combination with biologics as effective 2L options. Escalating to a triplet may add some efficacy at the expense of added toxicity. The rapidly changing treatment landscape for advanced gastric cancer includes increasing options for refractory disease. With multiple first-line platinum-based regimens, identification of those with the best benefit-to-risk ratio may provide guidance on treatment sequencing strategies. This article presents findings from the published literature of randomized controlled trials that included a first-line platinum/fluoropyrimidine combination and, for second-line trials, patients with platinum/fluoropyrimidine-refractory disease. This guiding summary could be a tool for clinicians to identify the optimal first-line regimen(s) followed by a strategy for subsequent regimens.
Sections du résumé
BACKGROUND
Platinum and fluoropyrimidine combinations typically comprise first-line (1L) therapy in advanced gastric cancer or gastroesophageal junction adenocarcinoma (G/GEA), although controversy exists regarding the use of 5doublet versus triplet cytotoxic regimens. Historically, second-line (2L) and third-line or later (3L+) therapy has been fragmented. Recent trials have increased the need for optimal treatment sequencing in advanced G/GEA.
MATERIALS AND METHODS
We conducted a systematic search of peer-reviewed manuscripts of randomized clinical trials examining 1L, 2L, and 3L+ therapy for advanced G/GEA published from 2009 through November 19, 2019. When available, overall survival, progression-free survival, time to progression, overall response rate, and toxicity were extracted from each and compared descriptively.
RESULTS
In 1L therapy, chemotherapy triplets demonstrated variable efficacy improvements with invariable increased toxicity compared with platinum/fluoropyrimidine doublets. Currently, the only published report of positive outcomes using biologics in 1L describes adding trastuzumab in HER2-overexpressing advanced G/GEA. In 2L, doublet chemotherapy regimens are not uniformly more efficacious than single-agent taxanes or irinotecan, and ramucirumab has demonstrated improved outcomes both as monotherapy and in combination.
CONCLUSION
For advanced G/GEA, review of trial results from 2009-2019 support 1L therapy with platinum and fluoropyrimidine and sequencing with taxanes or irinotecan in combination with biologics as effective 2L options. Escalating to a triplet may add some efficacy at the expense of added toxicity.
IMPLICATIONS FOR PRACTICE
The rapidly changing treatment landscape for advanced gastric cancer includes increasing options for refractory disease. With multiple first-line platinum-based regimens, identification of those with the best benefit-to-risk ratio may provide guidance on treatment sequencing strategies. This article presents findings from the published literature of randomized controlled trials that included a first-line platinum/fluoropyrimidine combination and, for second-line trials, patients with platinum/fluoropyrimidine-refractory disease. This guiding summary could be a tool for clinicians to identify the optimal first-line regimen(s) followed by a strategy for subsequent regimens.
Identifiants
pubmed: 34288262
doi: 10.1002/onco.13907
pmc: PMC8488781
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1704-e1729Informations de copyright
© 2021 ELI LILLY AND COMPANY. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
Références
J Clin Oncol. 2017 Aug 1;35(22):2558-2567
pubmed: 28574779
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Lancet Oncol. 2018 Oct;19(10):1372-1384
pubmed: 30217672
Eur J Cancer. 2015 May;51(7):808-16
pubmed: 25797356
Cancer Chemother Pharmacol. 2013 Feb;71(2):481-8
pubmed: 23192279
Gastric Cancer. 2015 Jan;18(1):168-76
pubmed: 24557418
J Clin Oncol. 2014 Jul 1;32(19):2039-49
pubmed: 24868024
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
J Clin Oncol. 2016 Feb 10;34(5):443-51
pubmed: 26628478
Lancet Oncol. 2017 May;18(5):640-653
pubmed: 28343975
Ann Oncol. 2017 Jun 1;28(6):1316-1324
pubmed: 29177434
Gastric Cancer. 2018 Sep;21(5):738-744
pubmed: 29392573
Gastric Cancer. 2015 Oct;18(4):824-32
pubmed: 25185971
Ann Oncol. 2018 May 1;29(5):1220-1226
pubmed: 29438463
J Clin Oncol. 2013 Sep 10;31(26):3219-25
pubmed: 23918952
JAMA Oncol. 2020 Oct 1;6(10):1571-1580
pubmed: 32880601
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
World J Gastroenterol. 2019 Oct 14;25(38):5773-5788
pubmed: 31636471
World J Gastroenterol. 2006 Jan 14;12(2):204-13
pubmed: 16482619
J Clin Oncol. 2013 Dec 10;31(35):4438-44
pubmed: 24190112
J Clin Oncol. 2006 Jan 20;24(3):394-400
pubmed: 16421419
Eur J Cancer. 2011 Oct;47(15):2306-14
pubmed: 21742485
J Clin Oncol. 2016 May 1;34(13):1448-54
pubmed: 26884585
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Clin Oncol. 2016 Jun;21(3):557-65
pubmed: 26547424
Lancet Oncol. 2019 Mar;20(3):420-435
pubmed: 30718072
J Clin Oncol. 2015 Nov 20;33(33):3858-65
pubmed: 26282658
Oncologist. 2019 Jan;24(1):18-e24
pubmed: 30126861
Ann Oncol. 2017 Sep 1;28(9):2142-2148
pubmed: 28911091
Lancet. 2015 May 9;385(9980):1843-52
pubmed: 25862517
J Clin Oncol. 2016 Aug 10;34(23):2736-42
pubmed: 27382098
J Natl Compr Canc Netw. 2016 Oct;14(10):1286-1312
pubmed: 27697982
Br J Cancer. 2012 Apr 24;106(9):1469-74
pubmed: 22460270
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
Lancet Oncol. 2018 Nov;19(11):1437-1448
pubmed: 30355453
Eur J Cancer. 2014 May;50(8):1437-45
pubmed: 24560487
Gastric Cancer. 2020 Jan;23(1):143-153
pubmed: 31087200
J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28
pubmed: 24366758
Oncologist. 2019 Apr;24(4):475-482
pubmed: 30470690
Ann Oncol. 2015 Oct;26(10):2097-101
pubmed: 26216386
J Clin Oncol. 2018 Oct 1;36(28):2836-2844
pubmed: 30110194
Gastric Cancer. 2016 Jul;19(3):919-26
pubmed: 26474989
N Engl J Med. 2018 Jul 26;379(4):396-397
pubmed: 30044940
J Clin Oncol. 2010 Mar 20;28(9):1547-53
pubmed: 20159816
Nat Med. 2018 Sep;24(9):1449-1458
pubmed: 30013197
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004064
pubmed: 20238327
Gastric Cancer. 2016 Jul;19(3):927-38
pubmed: 26510663
Bull Cancer. 2015 Apr;102(4):324-31
pubmed: 25744576
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
J Clin Oncol. 2012 May 1;30(13):1513-8
pubmed: 22412140
J Clin Oncol. 2016 Aug 10;34(23):2728-35
pubmed: 27325864
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Eur J Cancer. 2015 Mar;51(4):482-488
pubmed: 25661103
J Clin Oncol. 2015 Nov 20;33(33):3874-9
pubmed: 26438119
Lancet Oncol. 2017 Nov;18(11):1467-1482
pubmed: 28958504
Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287
pubmed: 28404157
Lancet Oncol. 2014 Jan;15(1):78-86
pubmed: 24332238
J Clin Oncol. 2017 Feb;35(4):475-477
pubmed: 28129519
Cancer Treat Rev. 2010 Aug;36(5):384-92
pubmed: 20176443
Drug Des Devel Ther. 2016 Jul 25;10:2353-8
pubmed: 27524882
Ann Oncol. 2015 Jan;26(1):149-156
pubmed: 25416687
Ann Oncol. 2018 Oct 1;29(10):2052-2060
pubmed: 30052729
Gastric Cancer. 2016 Jul;19(3):902-10
pubmed: 26386560
JAMA Oncol. 2021 Jun 1;7(6):895-902
pubmed: 33792646
Gastric Cancer. 2018 Sep;21(5):782-791
pubmed: 29488121
Cancer Res Treat. 2017 Jul;49(3):706-716
pubmed: 27764906
Ann Oncol. 2009 Apr;20(4):666-73
pubmed: 19153121
BMC Cancer. 2016 Aug 31;16:699
pubmed: 27582078
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510
pubmed: 31101534
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Anticancer Res. 2015 Jun;35(6):3531-6
pubmed: 26026121
J Clin Oncol. 2020 Jun 10;38(17):1919-1927
pubmed: 32208960
Ann Oncol. 2015 Jan;26(1):141-148
pubmed: 25316259
JAMA Oncol. 2017 May 1;3(5):620-627
pubmed: 27918764
Qual Life Res. 2009 Sep;18(7):853-61
pubmed: 19568958
Expert Opin Biol Ther. 2014 Sep;14(9):1319-32
pubmed: 24881691
Ther Adv Med Oncol. 2019 Aug 28;11:1758835919867522
pubmed: 31489035
Ann Oncol. 2015 Sep;26(9):1916-1922
pubmed: 26109630
Ann Oncol. 2013 Jun;24(6):1567-73
pubmed: 23406728
Cancer Discov. 2021 Feb;11(2):308-325
pubmed: 33234578
J Clin Oncol. 2008 Mar 20;26(9):1435-42
pubmed: 18349393
Clin Cancer Res. 2017 Oct 1;23(19):5671-5678
pubmed: 28655793
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet Oncol. 2013 May;14(6):490-9
pubmed: 23594786
Lancet Oncol. 2017 Dec;18(12):1637-1651
pubmed: 29103871
Lancet Oncol. 2013 May;14(6):481-9
pubmed: 23594787
Oncotarget. 2015 Oct 27;6(33):35107-15
pubmed: 26439700
J Gastroenterol Hepatol. 2016 Mar;31(3):581-9
pubmed: 26317322
J Clin Med. 2020 Sep 22;9(9):
pubmed: 32971757
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
J Clin Oncol. 2006 Nov 1;24(31):4991-7
pubmed: 17075117
Eur J Cancer. 2017 Sep;83:32-42
pubmed: 28711577
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
J Clin Oncol. 2011 Oct 20;29(30):3968-76
pubmed: 21844504
J Clin Oncol. 2021 Mar 20;39(9):966-977
pubmed: 33197226
Gastric Cancer. 2016 Jan;19(1):234-44
pubmed: 25604851
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
JAMA Oncol. 2020 Aug 1;6(8):1231-1240
pubmed: 32469386
J Clin Oncol. 2014 Nov 1;32(31):3520-6
pubmed: 25287828
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
Gastric Cancer. 2019 Mar;22(2):344-354
pubmed: 30506519
J Clin Oncol. 2013 Nov 1;31(31):3935-43
pubmed: 24043745
Eur J Cancer. 2014 Nov;50(16):2822-30
pubmed: 25218337
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Lancet. 2021 Jul 3;398(10294):27-40
pubmed: 34102137
Br J Cancer. 2014 Jan 21;110(2):271-7
pubmed: 24281004
Lancet Oncol. 2014 Jul;15(8):894-904
pubmed: 24950987